|
Post by nylefty on Sept 2, 2019 22:44:01 GMT -5
What it does is put "Afrezza", "inhaled" and "Exubera" together. I don't feel that association with Exubera, a failed inhaled insulin, is good for Afrezza. Was Exubera really a "failed" inhaled insulin or did Pfizer make a business decision not to make the market for afrezza knowing how much better afrezza was and how disruptive it would have been to the market, if the market was all a buzz about the inhaled insulin miracle Exubera? A few years back I had the chance to talk with the lead scientist for Exubera. He told me it was the latter and told me the cancer scare was a made up scare to soar the market for afrezza. His words not mine. He was also one of the most knowledgeable people I have talk to about afrezza. I will say they did a hell of a job soaring the market. Soar? I'd love to see Afrezza soar. soar
/sôr/
verb
increase rapidly above the usual level. "the cost of living continued to soar" synonyms: increase rapidly, shoot up, rise rapidly, escalate, spiral upwards
|
|
|
Post by longliner on Sept 2, 2019 23:45:57 GMT -5
Like a bird baby!!!
|
|
|
Post by mytakeonit on Sept 2, 2019 23:59:00 GMT -5
Ahhh ... okay. So, like a baby EAGLE !!!
But, that's mytakeonit
|
|
|
Post by longliner on Sept 3, 2019 1:11:16 GMT -5
Ahhh ... okay. So, like a baby EAGLE !!! But, that's mytakeonit Heck, i'd take a Swallow!! But, it is late.
|
|
|
Post by agedhippie on Sept 3, 2019 11:40:07 GMT -5
What it does is put "Afrezza", "inhaled" and "Exubera" together. I don't feel that association with Exubera, a failed inhaled insulin, is good for Afrezza. Was Exubera really a "failed" inhaled insulin or did Pfizer make a business decision not to make the market for afrezza knowing how much better afrezza was and how disruptive it would have been to the market, if the market was all a buzz about the inhaled insulin miracle Exubera? A few years back I had the chance to talk with the lead scientist for Exubera. He told me it was the latter and told me the cancer scare was a made up scare to soar the market for afrezza. His words not mine. He was also one of the most knowledgeable people I have talk to about afrezza. I will say they did a hell of a job soaring the market. This is an interesting study. The one big thing afrezza and Exubera share is they eliminate all the subq issues. The benefits shown in this study would also apply for afrezza. I like it. Pfizer spent around $2.8bn on Exubera so they must have done their diligence. I would have expected Pfizer be relying on building a big enough head start in the market to protect themselves from competition which they most likely saw coming from deep pocketed pharmas like Novo Nordisk, and Eli Lilly who were developing their own inhaled insulins. Just looking at the timing; Exubera was launched in 2006, Mannkind got the CRL when they filed with the FDA 5 years later so the best case was that the FDA had approved back then in 2011 and there was a 2012 launch putting Afrezza on the market 6 years after Exubera. Pfizer told the market it was predicting Exubera would be generating $1.5bn revenue by 2010. What happened was that a year after launch the final quarter revenue for Exubera was $4M. Lots of things killed Exubera, but I find it hard to believe that a fear of the arrival of Afrezza five years later was one of them. I could believe though that the cancer scare was made up after the fact to salt the ground for inhaled insulin in general though. I can imagine that Pfizer might be reluctant to see big pharmas like Novo Nordisk, and particularly Eli Lilly, benefiting from the inhaled insulin market. All of that said, you have the benefit of having talked to someone directly involved which I don't.
|
|
|
Post by mango on Sept 3, 2019 12:42:28 GMT -5
|
|
|
Post by agedhippie on Sept 3, 2019 13:03:56 GMT -5
That's the paper this thread is about.
|
|
|
Post by mango on Sept 3, 2019 13:13:45 GMT -5
|
|
|
Post by agedhippie on Sept 3, 2019 15:17:24 GMT -5
That one's new. Off for a read....
|
|
|
Post by peppy on Sept 3, 2019 15:19:06 GMT -5
|
|